BI tims TOF fleX with MALDI-2 mass spectrometer

摘要 细胞质谱学设备已经为单个细胞的表征创建了独特的方案 和细胞器，用于组织的高空间分辨率质谱学成像和相关 分子成像。这些测量方法被广泛的NIH支持的研究人员使用， 在当地的伊利诺伊大学香槟分校(UIUC)，在伊利诺伊州的合作机构， 印第安纳州和威斯康星州，以及全国。最重要的需要是取代两个独立的十年前的工具 使用一种新的基质辅助激光解吸电离(MALDI)质谱仪，大大增强了 检测极限、质量分辨率、离子迁移率分离、分析等方面的性能规格 速度和空间分辨率，以及其他方面的进步。更具体地说，请求的Bruker TimsTOF Flex MALDI-2系统结合了多种设计改进，包括MALDI-2后电离、陷阱 离子迁移率、并行累加串行碎片、双源和许多其他设计改进 与其他工具相比。这些高级功能和相关的品质因数使 适用于需要单细胞和组织成像测量的一系列NIH支持的用户。主要分子 靶标包括脂质、代谢物、多肽(包括内源性D-氨基酸多肽)和 蛋白质。由于该仪器被认为是UIUC的战略收购，政府正在提供 2-5年支持服务合同的机构资金。这项文书将直接惠及三个国家卫生研究院-- 支持的中心和十几个额外的NIH支持的主要用户；对广泛投资组合的研究 将通过购买Bruker timsTOF FLEX MALDI-2仪器来推动研究项目的实施。

Summary The Cellular Mass Spectrometry Facility has created unique protocols for the characterization of individual cells and cellular organelles, for high spatial resolution mass spectrometry imaging of tissues and for correlated molecular imaging. These measurement approaches are used by a broad range of NIH-supported researchers, locally at the University of Illinois Urbana-Champaign (UIUC), regionally at collaborating institutions in Illinois, Indiana and Wisconsin, and nationally. The overarching need is to replace two separate decade-old instruments with a new matrix assisted laser-desorption ionization (MALDI) mass spectrometer that has greatly enhanced performance specifications in terms of detection limits, mass resolution, ion mobility separations, analyses speeds, and spatial resolution, among other advancements. More specifically, the requested Bruker timsTOF fleX MALDI-2 system incorporates multiple design improvements, including MALDI-2 post-ionization, trapped ion mobility, parallel accumulation serial fragmentation, dual sources, and many other design improvements compared to alternative instruments. These advanced features and the associated figures of merit are enabling for a range of NIH-supported users requiring single cell and tissue imaging measurements. The major molecular targets include lipids, metabolites, peptides (including endogenous D-amino acid-containing peptides) and proteins. Because the instrument is considered a strategic acquisition by UIUC, the administration is supplying institutional funds to support the service contracts in years 2–5. This instrument will directly benefit three NIH- supported centers and more than a dozen additional NIH-supported major users; the research of a broad portfolio of research projects will be catalyzed with the acquisition of the Bruker timsTOF flex MALDI-2 instrument.